These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 34415673)

  • 1. Evaluation of drug-drug interaction potential between omecamtiv mecarbil and rosuvastatin, a BCRP substrate, with a clinical study in healthy subjects and using a physiologically-based pharmacokinetic model.
    Trivedi A; Sohn W; Kulkarni P; Jafarinasabian P; Zhang H; Spring M; Flach S; Abbasi S; Wahlstrom J; Lee E; Dutta S
    Clin Transl Sci; 2021 Nov; 14(6):2510-2520. PubMed ID: 34415673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Assessment of Breast Cancer Resistance Protein (BCRP)-Mediated Drug-Drug Interactions of Sepiapterin with Curcumin and Rosuvastatin in Healthy Volunteers.
    Gao L; Kaushik D; Ingalls K; Milner S; Smith N; Kong R
    Drugs R D; 2024 Sep; 24(3):477-487. PubMed ID: 39316278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physiologically Based Pharmacokinetic Modeling of Rosuvastatin to Predict Transporter-Mediated Drug-Drug Interactions.
    Hanke N; Gómez-Mantilla JD; Ishiguro N; Stopfer P; Nock V
    Pharm Res; 2021 Oct; 38(10):1645-1661. PubMed ID: 34664206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of enzalutamide on PK of P-gp and BCRP substrates in cancer patients: CYP450 induction may not always predict overall effect on transporters.
    Poondru S; Ghicavii V; Khosravan R; Manchandani P; Heo N; Moy S; Wojtkowski T; Patton M; Haas GP
    Clin Transl Sci; 2022 May; 15(5):1131-1142. PubMed ID: 35118821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigation of the Effect of Lasmiditan on the Pharmacokinetics of P-Glycoprotein and Breast Cancer Resistance Protein Substrates.
    Luffer-Atlas D; Wilbraham D; Posada MM; Landry J; Tsai M; Pearlman EM
    J Clin Pharmacol; 2024 Jan; 64(1):94-102. PubMed ID: 37566903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pharmacokinetic drug-drug interaction study between rosuvastatin and emvododstat, a potent anti-SARS-CoV-2 (COVID-19) DHODH (dihydroorotate dehydrogenase) inhibitor.
    Morton TL; Laskin OL; Kaushik D; Lee L; Ma J; Kristensen A; O'Keefe K; Golden L; Klein M; Kong R
    Pharmacol Res Perspect; 2023 Apr; 11(2):e01076. PubMed ID: 36938928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Upadacitinib on the Pharmacokinetics of Rosuvastatin or Atorvastatin in Healthy Subjects.
    Mohamed MF; Coppola S; Feng T; Camp HS; Kim E; Othman AA
    Clin Pharmacol Drug Dev; 2021 Nov; 10(11):1335-1344. PubMed ID: 34109764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The dual orexin receptor antagonist daridorexant does not affect the pharmacokinetics of the BCRP substrate rosuvastatin.
    Zenklusen I; Muehlan C; Ulc I; Liška J; Dingemanse J
    Clin Exp Pharmacol Physiol; 2020 Nov; 47(11):1843-1849. PubMed ID: 32603512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calibrating the In Vitro-In Vivo Correlation for OATP-Mediated Drug-Drug Interactions with Rosuvastatin Using Static and PBPK Models.
    Sane R; Cheung KWK; Kovács P; Farasyn T; Li R; Bui A; Musib L; Kis E; Plise E; Gáborik Z
    Drug Metab Dispos; 2020 Dec; 48(12):1264-1270. PubMed ID: 33037044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic Drug-Drug Interaction Study of Omecamtiv Mecarbil With Omeprazole, a Proton Pump Inhibitor, in Healthy Subjects.
    Trivedi A; Sohn W; Jafarinasabian P; Zhang H; Terminello B; Flach S; Abbasi S; Dutta S; Lee E
    Clin Pharmacol Drug Dev; 2022 Jan; 11(1):129-133. PubMed ID: 34272833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic Drug-Drug Interaction Study of Omecamtiv Mecarbil With Amiodarone and Digoxin in Healthy Subjects.
    Trivedi A; Sohn W; Hsu CP; Jafarinasabian P; Zhang H; Hutton S; Flach S; Abbasi S; Dutta S; Lee E
    Clin Pharmacol Drug Dev; 2022 Mar; 11(3):388-396. PubMed ID: 34634185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Macitentan on the Pharmacokinetics of the Breast Cancer Resistance Protein Substrates, Rosuvastatin and Riociguat, in Healthy Male Subjects.
    Csonka D; Bruderer S; Schultz A; Soergel M; Stepanova R; Sabattini G; Perez-Ruixo JJ
    Clin Drug Investig; 2019 Dec; 39(12):1223-1232. PubMed ID: 31552642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Multiple-Dose Administration of Aprocitentan on the Pharmacokinetics of Rosuvastatin.
    Sidharta PN; Dingemanse J
    Clin Pharmacol Drug Dev; 2020 Nov; 9(8):995-1002. PubMed ID: 32592633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative prediction of breast cancer resistant protein mediated drug-drug interactions using physiologically-based pharmacokinetic modeling.
    Costales C; Lin J; Kimoto E; Yamazaki S; Gosset JR; Rodrigues AD; Lazzaro S; West MA; West M; Varma MVS
    CPT Pharmacometrics Syst Pharmacol; 2021 Sep; 10(9):1018-1031. PubMed ID: 34164937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of Transporter Polymorphisms as a Factor in a BCRP Drug Interaction Study With Lanabecestat.
    Willis BA; Andersen SW; Ayan-Oshodi M; James DE; Liffick E; Hillgren K; Guo Y; Monk SA
    J Clin Pharmacol; 2020 Jan; 60(1):107-116. PubMed ID: 31378968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of multiple-dose osimertinib on the pharmacokinetics of simvastatin and rosuvastatin.
    Harvey RD; Aransay NR; Isambert N; Lee JS; Arkenau T; Vansteenkiste J; Dickinson PA; Bui K; Weilert D; So K; Thomas K; Vishwanathan K
    Br J Clin Pharmacol; 2018 Dec; 84(12):2877-2888. PubMed ID: 30171779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Omecamtiv Mecarbil on the Pharmacokinetics of Metformin, a Probe Substrate for MATE1/MATE2-K, in Healthy Subjects.
    Trivedi A; Oberoi RK; Jafarinasabian P; Zhang H; Spring M; Flach S; Abbasi S; Dutta S; Lee E
    Clin Drug Investig; 2021 Jul; 41(7):647-652. PubMed ID: 34097256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulatory guidelines do not accurately predict tolvaptan and metabolite interactions at BCRP, OATP1B1, and OAT3 transporters.
    Shoaf SE; Bricmont P; Repella Gordon J
    Clin Transl Sci; 2021 Jul; 14(4):1535-1542. PubMed ID: 33742787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Febuxostat, But Not Allopurinol, Markedly Raises the Plasma Concentrations of the Breast Cancer Resistance Protein Substrate Rosuvastatin.
    Lehtisalo M; Keskitalo JE; Tornio A; Lapatto-Reiniluoto O; Deng F; Jaatinen T; Viinamäki J; Neuvonen M; Backman JT; Niemi M
    Clin Transl Sci; 2020 Nov; 13(6):1236-1243. PubMed ID: 32453913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Drug-Drug Interaction Between Vatiquinone, a 15-Lipoxygenase Inhibitor, and Rosuvastatin, a Breast Cancer Resistance Protein Substrate.
    Lee L; Murase K; Ma J; Thoolen M
    Clin Pharmacol Drug Dev; 2023 Mar; 12(3):279-286. PubMed ID: 36478438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.